Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical Co., Inc.
	Logo since 2003
Trade name	Hisamitsu
Native name	久光製薬株式会社
Romanized name	Hisamitsu Seiyaku kabushiki gaisha
Company type	Public KK
Traded as	TYO: 4530; NAG: 4530; FSE: 4530
Industry	Pharmaceuticals
Founded	1847
Headquarters	Tosu, Saga 841-0017, Japan (Kyushu head office); Marunouchi, Chiyoda, Tokyo100-6330, Japan (Tokyo head office)
Area served	Worldwide
Key people	Hirotaka Nakatomi; (President and CEO)
Products	Salonpas and other pain relief products; Robitussin, Caltrate, Advil (Japan-only); Eye drops; Anti fungal, anti-inflammatory, dermatologic, central nerve system, respiratory system medicines;
Revenue	JPY 150.63 billion (US$1.47 billion) (FY 2013)
Net income	JPY 21.35 billion (US$209.5 million) (FY 2013)
Number of employees	2,949 (consolidated, as of 28 February 2014)
Website	global.hisamitsu
	Footnotes / references;

The Hisamitsu Pharmaceutical Co., Inc. (久光製薬株式会社, Hisamitsu Seiyaku kabushiki gaisha), headquartered in Saga and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug (OTC) products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology (TDDS) since the introduction of its original line of patches in 1903.

Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration (FDA).